Nkarta (NKTX) Competitors $2.05 -0.07 (-3.30%) Closing price 05/1/2025 04:00 PM EasternExtended Trading$2.07 +0.02 (+0.93%) As of 09:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NKTX vs. COGT, RLAY, VALN, TYRA, MGTX, SION, KURA, OPT, PRTA, and URGNShould you be buying Nkarta stock or one of its competitors? The main competitors of Nkarta include Cogent Biosciences (COGT), Relay Therapeutics (RLAY), Valneva (VALN), Tyra Biosciences (TYRA), MeiraGTx (MGTX), Sionna Therapeutics (SION), Kura Oncology (KURA), Opthea (OPT), Prothena (PRTA), and UroGen Pharma (URGN). These companies are all part of the "pharmaceutical products" industry. Nkarta vs. Cogent Biosciences Relay Therapeutics Valneva Tyra Biosciences MeiraGTx Sionna Therapeutics Kura Oncology Opthea Prothena UroGen Pharma Cogent Biosciences (NASDAQ:COGT) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability, community ranking and risk. Do institutionals and insiders hold more shares of COGT or NKTX? 80.5% of Nkarta shares are held by institutional investors. 5.9% of Cogent Biosciences shares are held by insiders. Comparatively, 8.7% of Nkarta shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community favor COGT or NKTX? Cogent Biosciences received 226 more outperform votes than Nkarta when rated by MarketBeat users. However, 78.05% of users gave Nkarta an outperform vote while only 70.22% of users gave Cogent Biosciences an outperform vote. CompanyUnderperformOutperformCogent BiosciencesOutperform Votes29070.22% Underperform Votes12329.78% NkartaOutperform Votes6478.05% Underperform Votes1821.95% Is COGT or NKTX more profitable? Nkarta's return on equity of -27.13% beat Cogent Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Cogent BiosciencesN/A -112.55% -60.44% Nkarta N/A -27.13%-21.67% Does the media favor COGT or NKTX? In the previous week, Cogent Biosciences had 11 more articles in the media than Nkarta. MarketBeat recorded 13 mentions for Cogent Biosciences and 2 mentions for Nkarta. Nkarta's average media sentiment score of 1.72 beat Cogent Biosciences' score of 0.88 indicating that Nkarta is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 4 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nkarta 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has more risk & volatility, COGT or NKTX? Cogent Biosciences has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500. Comparatively, Nkarta has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Which has stronger valuation & earnings, COGT or NKTX? Cogent Biosciences is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCogent BiosciencesN/AN/A-$192.41M-$1.94-2.90NkartaN/AN/A-$117.50M-$1.66-1.23 Do analysts recommend COGT or NKTX? Cogent Biosciences presently has a consensus price target of $14.43, suggesting a potential upside of 156.28%. Nkarta has a consensus price target of $14.86, suggesting a potential upside of 624.74%. Given Nkarta's stronger consensus rating and higher possible upside, analysts plainly believe Nkarta is more favorable than Cogent Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cogent Biosciences 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.75Nkarta 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 SummaryNkarta beats Cogent Biosciences on 13 of the 16 factors compared between the two stocks. Get Nkarta News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NKTX vs. The Competition Export to ExcelMetricNkartaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$145.46M$6.84B$5.53B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-1.097.3222.5118.54Price / SalesN/A241.49397.62103.30Price / CashN/A65.8538.1834.62Price / Book0.376.486.734.25Net Income-$117.50M$143.41M$3.22B$248.18M7 Day Performance-2.84%2.58%1.38%1.03%1 Month Performance7.33%5.00%2.79%2.70%1 Year Performance-72.78%-3.72%15.41%4.05% Nkarta Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NKTXNkarta2.8398 of 5 stars$2.05-3.3%$14.86+624.7%-72.6%$145.46MN/A-1.09140Upcoming EarningsPositive NewsCOGTCogent Biosciences2.1736 of 5 stars$4.91+5.8%$14.43+193.9%-18.8%$559.03MN/A-1.9880Upcoming EarningsOptions VolumeAnalyst RevisionRLAYRelay Therapeutics1.932 of 5 stars$3.26+1.9%$18.36+463.3%-50.6%$552.64M$10.01M-1.25330News CoveragePositive NewsGap DownVALNValneva2.5153 of 5 stars$6.57-6.5%$16.00+143.5%-17.0%$549.49M$169.58M-50.54700Upcoming EarningsGap DownTYRATyra Biosciences1.8296 of 5 stars$10.34+3.0%$30.83+198.2%-42.7%$548.95MN/A-6.4220Upcoming EarningsNews CoveragePositive NewsMGTXMeiraGTx4.5537 of 5 stars$6.81+1.6%$24.50+259.8%+45.5%$537.00M$33.28M-5.63300Upcoming EarningsShort Interest ↑News CoverageSIONSionna TherapeuticsN/A$12.04-0.8%$38.50+219.8%N/A$531.25MN/A0.0035Positive NewsGap DownKURAKura Oncology4.1265 of 5 stars$6.51+1.2%$25.50+291.7%-68.0%$525.87M$53.88M-2.76130Earnings ReportAnalyst ForecastNews CoveragePositive NewsOPTOpthea0.8148 of 5 stars$3.41+7.2%$1.33-60.9%+0.9%$524.84M$87,666.000.008News CoverageGap UpPRTAProthena3.462 of 5 stars$9.65-0.5%$55.00+469.9%-59.3%$519.43M$135.16M-4.20130Upcoming EarningsNews CoverageURGNUroGen Pharma4.2934 of 5 stars$11.26+14.1%$32.86+191.8%-20.8%$519.02M$90.40M-3.57200Analyst ForecastAnalyst RevisionNews CoverageHigh Trading Volume Related Companies and Tools Related Companies Cogent Biosciences Competitors Relay Therapeutics Competitors Valneva Competitors Tyra Biosciences Competitors MeiraGTx Competitors Sionna Therapeutics Competitors Kura Oncology Competitors Opthea Competitors Prothena Competitors UroGen Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NKTX) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMassive dollar overhaul underway in D.C.?Trump's plan to save the U.S. Dollar The U.S. Dollar is crashing, and our reserve currency status is now in...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nkarta, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nkarta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
